Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

See all formats and pricing
More options …
Volume 56, Issue 1


Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

Zenthuja Sivalingam / Sanne Bøjet Larsen / Erik Lerkevang Grove
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
  • Faculty of Health, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Anne-Mette Hvas
  • Faculty of Health, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark
  • Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Steen Dalby Kristensen
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
  • Faculty of Health, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Nils Erik Magnusson
  • Corresponding author
  • The Medical Research Laboratories, Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Nørrebrogade 44, 8000 Aarhus C, Denmark
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-06-23 | DOI: https://doi.org/10.1515/cclm-2017-0120


Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.

Keywords: atherosclerosis; biomarkers; cardiovascular disease; inflammation; neutrophil gelatinase-associated lipocalin (NGAL)


Coronary artery disease (CAD) is caused by atherosclerosis and is the main cause of mortality worldwide [1]. Atherosclerosis is regarded a chronic vascular inflammatory disease with a complex multifactorial pathophysiology. Inflammation within the atherosclerotic plaque has been suggested to promote plaque instability and disruption [2].

Previously, elevated levels of high-sensitive C-reactive protein (hs-CRP) have been associated with a 45% increased risk of cardiovascular events in patients without established CAD [3]. In patients with CAD, increased hs-CRP is considered a risk marker of adverse events [4]. Thus, inflammatory biomarkers may have the potential to improve risk assessment in CAD patients.

It has been hypothesised that neutrophil gelatinase-associated lipocalin (NGAL) may be a marker of atherosclerosis, which is supported by recent data demonstrating excessive expression of NGAL in atherosclerotic plaques in areas with high proteolytic activity [5]. The role of NGAL in CAD patients has been suggested to involve matrix metalloproteinase-9 (MMP-9) [5]. Other studies report that NGAL may be a risk marker in heart failure (HF) patients [6] and in patients undergoing cardiac surgery [7].

In this review, analytical approaches and the role of NGAL in cardiovascular disease (CVD) will be summarised and discussed focusing on the potential role of NGAL as a risk marker of atherosclerosis.

Materials and methods

In January 2017, we conducted a systematic literature search on PubMed. The search was carried out both on basis of medical subject headings (MESH) tree and as a text search, and it was limited to English language and year of publication, ranging from 2000 to 2017, using the MESH terms “Neutrophil gelatinase-associated protein and coronary artery disease”, “NGAL and cardiovascular disease”, and “NGAL assay”. In addition, reference lists were studied, and manual searches performed. The primary focus of this review is to outline and summarise the characteristics of NGAL in CVD. Consequently, the review is limited to clinical trials and experimental studies in cardiac settings. So far, many studies have demonstrated NGAL as a novel biomarker for early diagnosis of acute kidney injury (AKI). Recent studies suggest that NGAL is a promising biomarker of CVD and is hypothesised to reflect the degree of atherosclerotic inflammation in patients with CAD.

Main characteristics of NGAL

NGAL is a 25 kilodalton (kDa) human protein belonging to the lipocalin superfamily [8]. The human neutrophils are the main source of plasma NGAL, which are constitutively expressed and synthesized at early-myelocyte stages of granulopoiesis in the bone marrow [9]. Consequently, the mature peripheral neutrophils only store NGAL protein in granules.

It has been demonstrated that NGAL functions as an inflammatory modulator of the innate immune system [10]. This is supported by the fact that NGAL is capable of binding siderophores, reducing the amount of siderophore-bound iron available to bacteria inhibiting bacterial growth by depleting their intracellular iron stores [11].

The complex between NGAL and MMP-9 inhibits degradation of MMP-9 thereby extending the proteolytic activity of MMP-9 (Figure 1) [13]. By enhancing the activity of MMP-9, the degradation of the basement membranes and extracellular matrix increases, a process recognised in the progression of unstable atherosclerotic plaques in arteries [5]. In atherosclerotic plaques, the collagen degradation by MMP-9 is high, which causes an unstable fibrous cap and makes the atherosclerotic plaque more susceptible to erosion and rupture [5].

The role of NGAL and MMP-9 in the atherosclerosis. At the site of plaque rupture (tunica intima), activated macrophages and mast cells produce proteases (MMP-9), which destabilise the atherosclerotic plaque. The molecules degrade the fibrous cap and collagen and make the plaque more prone to rupture. A complex formation between neutrophil gelatinase associated lipocalin and matrix metalloproteinase 9 (MMP-9) protects and prolongs the proteolytic activity of MMP-9 inducing plaque rupture and risk of thrombus formation [12].
Figure 1:

The role of NGAL and MMP-9 in the atherosclerosis.

At the site of plaque rupture (tunica intima), activated macrophages and mast cells produce proteases (MMP-9), which destabilise the atherosclerotic plaque. The molecules degrade the fibrous cap and collagen and make the plaque more prone to rupture. A complex formation between neutrophil gelatinase associated lipocalin and matrix metalloproteinase 9 (MMP-9) protects and prolongs the proteolytic activity of MMP-9 inducing plaque rupture and risk of thrombus formation [12].

Assessment of NGAL levels in blood and urine

Differences in NGAL cut-off levels for prediction of outcome in diseases and reference values in the healthy population have been observed in numerous reports [14]. Several factors contribute to the variation such as different clinical settings, biological variation, use of different assays, antibody configurations, anticoagulants, and storage conditions [15]. Different methods including commercial and in-house sandwich immunoassays and immunoblotting protocols have been used to determine NGAL in plasma, serum, and urine [16], [17], [18].

Pedersen et al. tested the use of enzyme-linked immunosorbent assay (ELISA) kit, using the manual procedure, (BioPorto Diagnostics) for NGAL in plasma and urine. In healthy adults, the median intra and inter-assay variation was <5% and <10% for plasma and urine, respectively [19]. Similar results have been reported in other studies [18], [20]. In the study by Pedersen et al., the highest inter-assay variation in urine was ≤18.6% and likely explained by interference of sedimentation factors, emphasising the importance of centrifuging urine samples before analysis. Moreover, in plasma it was demonstrated that haemolysis caused NGAL levels to increase, which may be explained by release of NGAL from ruptured leucocytes, a process also observed in serum samples following multiple freeze/thaw cycles. In plasma and urine NGAL samples, levels were not significantly affected by repetitive freeze/thaw cycles [19].

To accommodate standardised assays for inclusion of NGAL in the standard panel to screen kidney diseases, the analytical performance of automated biochemistry analysers have been evaluated (Table 1). Cavalier et al. [32] performed an analytical comparison between a rapid bedside fluorescence-based immunoassay NGAL method (Triage Meter, Biosite Inc.) and the automated Architect NGAL laboratory assay with ethylenediaminetetraacetic acid (EDTA) plasma and urine samples. Both assays correlated well with validated ELISA kits from BioPorto. The Architect assay was shown to provide precise results in the range 22.5–1315 μg/L with maximum error of ±20% and probability of 95%. Using the same conditions, the corresponding range for the Triage method was 619–722 μg/L, indicating high analytical variation of the Triage method [32].

Table 1:

Neutrophil gelatinase associated-lipocalin studies on reference ranges included in this review.

Hansen et al. [20] evaluated the turbidimetric NGAL Test™ from BioPorto with an automated method, Cobas 6000 c501 (Roche Diagnostics, Rotkreuz, Switzerland). The analytical performance was comparable to the automated Hitachi 917 in 40 matched samples of urine, Li-Hep plasma, and EDTA plasma. It was noted that NGAL levels were higher in Li-Hep plasma than in EDTA plasma, thus EDTA was recommended as anticoagulant.

Delanaye et al. [29] studied the biological variation of NGAL by measuring the absolute value of urinary NGAL and NGAL/creatinine ratio using an automated immuno-assay from Abbott Laboratories (Abbott Park, IL, USA) on the Architect platform. As the coefficient of variation (CV) for urinary NGAL was higher than the CV of NGAL/creatinine ratio, the authors recommended the use of NGAL/creatinine ratio to reduce intra-individual variation. Urinary NGAL variation was measured in healthy subjects only, thus the biological variation in patients with AKI or CVD remains unknown.

While several reference ranges for urine NGAL have been published, reference ranges for plasma NGAL have not yet been fully explored. Published reference ranges are summarised in Table 1.

NGAL and cardiovascular disease

NGAL in atherosclerotic plaques

In atherosclerotic plaques, thrombus formation is triggered by rupture of the plaque cap or endothelial erosion. Inside the plaque, inflammatory activity facilitates plaque instability and disruption [2]. The atheroma possesses inflammatory mediators, which inhibit smooth muscle growth and collagen production, and enhance the activity of MMP’s [12]. This also makes the atherosclerotic plaques unstable and vulnerable, potentially leading to plaque rupture.

Hemdahl et al. [5] analysed the association between NGAL expression in atherosclerotic plaques and myocardial infarction (MI) in mice exposed to hypoxic stress. Mice developing MI had higher concentrations of NGAL and MMP-9 than mice with stable atherosclerotic plaques. In atherosclerotic plaques retrieved from human carotid endarterectomy specimens, expression of NGAL and MMP-9 were detected in macrophages [5]. Yndestad et al. found that NGAL was over-expressed in the myocardium following MI in a rat model, and murine data suggests that mice deficient in the NGAL mouse orthologue were protected from development of aortic aneurysms [6], [33]. In patients undergoing surgery for infrarenal abdominal aortic aneurysms, NGAL/MMP-9 complexes were identified in the thrombus and in the interface between the thrombus and the underlying wall [34]. Furthermore, NGAL has also been associated with intraplaque hemorrhages of human carotid endarterectomy samples [35].

Although causality is not explicitly proven, these findings might suggest a pro-atherogenic action of NGAL via enzymatically active NGAL/MMP-9 complexes. However, further studies are needed to explore whether NGAL is an important and specific marker of atherosclerosis.

NGAL and acute coronary syndrome

The association between NGAL levels and risk scores (clinical and angiographical) has been studied in patients diagnosed with non-ST-segment elevation MI (NSTEMI) and compared with healthy individuals [36]. High levels of NGAL, hs-CRP, and leukocytes were observed in the patient group. Furthermore, NGAL correlated positively with the global registry of acute coronary events (GRACE) risk score (which estimates the 6-month mortality risk in patients with acute coronary syndrome [ACS]). The severity of CAD was assessed by the Gensini score (evaluates collateral circulation of the coronary arteries) and the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) (estimates the complexity of CAD) score showing increased NGAL levels in patients with intermediate and high SYNTAX scores compared to patients with low SYNTAX score [36].

Sahinarslan et al. reported that patients with acute MI had higher levels of plasma NGAL and leukocytes than stable CAD patients [37]. However, there was no correlation between plasma NGAL and the Gensini score. These findings were supported by Choi et al., who reported that NGAL levels were higher in patients with acute MI and unstable angina pectoris than stable CAD patients. However, the findings were not statistically significant, possibly due to a low number of patients diagnosed with ACS (n=11). Also, blood samples were collected at least 3 months after the acute event [38].

Akcay et al. [39] reported a poor prognosis in patients with high NGAL levels and ST-segment elevation MI (STEMI) treated with primary percutaneous coronary intervention (PCI) compared to patients admitted for elective PCI. Similarly, high NGAL levels independently predicted all-cause mortality and major adverse cardiac events (MACE) in STEMI patients treated with PCI [40]. Furthermore, the study showed that high levels of CRP and NGAL were related to poor outcomes, while low levels of NGAL and CRP were associated with decreased risk of MACE. Indeed, the risk still remained high when NGAL was elevated even though CRP was low [40]. This is consistent with findings by Zykov et al., who also reported that high NGAL level, is a strong predictor of all-cause mortality suggesting a high prognostic value of NGAL in patients with STEMI [41].

The majority of these studies (Table 2) suggest that NGAL has the potential to improve risk stratification in patients with ACS.

Table 2:

Summary of neutrophil gelatinase-associated lipocalin studies including patients with coronary artery disease.

NGAL in stable coronary artery disease

Only few studies have measured NGAL in stable CAD patients (Table 2), and so far, no causal relation between NGAL and stable CAD has been established.

Paulsson et al. [42] compared levels of neutrophils and MMP-9/NGAL complexes in stable CAD patients with age- and sex matched healthy individuals. Neutrophil levels did not differ between patients and healthy individuals, neither in peripheral blood nor at the site of intense inflammation. However, the concentration of interleukin-8 (IL-8), which stimulates the release of NGAL from neutrophil granules, was higher in patients than healthy individuals. This may contribute to the observed higher concentration of the MMP-9/NGAL complex in patients than healthy individuals and suggest a priming stage of circulating neutrophils in stable CAD patients [42].

Zografos et al. [43] reported that serum NGAL levels in stable CAD patients were significantly increased compared with patients with normal coronary arteries. Another study showed that patients with triple vessel disease had higher serum levels of NGAL than patients with single vessel disease [46]. Moreover, a positive association between NGAL and the SYNTAX score was reported. Patients with high levels of NGAL (>100 ng/mL) and brain natriuretic peptide (BNP) (>25 pg/mL) had a higher SYNTAX score than patients with low levels of NGAL (<100 ng/mL) and BNP (<25 pg/mL) [46].

Recently, Woitas et al. analysed the predictive role of plasma NGAL in CAD patients, including unstable and stable CAD patients and reported that plasma NGAL levels were independently related to all-cause mortality as well as CVD mortality after adjusting for conventional cardiovascular risk factors. However, when adjusting for creatinine levels, plasma NGAL did not predict all-cause mortality and CVD mortality [44]. Thus, the studies indicate that NGAL levels are higher in patients with ACS than in stable CAD patients, and that creatinine is a strong predictor of mortality [37], [45].

NGAL levels and acute kidney injury in cardiac surgery

AKI after cardiac surgery is a relatively frequent event, which causes dialysis, prolonged hospitalisation and increased in-hospital mortality [47]. A short summary of the studies on cardiac surgery and AKI are listed in Table 3.

Table 3:

Neutrophil gelatinase associated-lipocalin studies on cardiac surgery and AKI included in this review.

In one study, 21 children underwent cardiac surgery on extracorporeal circulation and developed postoperative AKI. A significant increase in urinary NGAL concentration was reported in these children [16]. Others found that plasma NGAL concentration tripled and remained significantly elevated in 120 children who developed AKI after cardiac surgery [48].

Similar findings have been reported in studies on adults. In patients who developed AKI after cardiac surgery, urinary NGAL peaked within 2–4 h postoperatively, whereas the concentration of serum NGAL did not increase significantly [47]. Tuladhar et al. [17] also studied the development of AKI after cardiac surgery. The plasma and urinary AUC of NGAL using receiver operating characteristic curves (ROC) were 0.80 and 0.96, respectively. This is in accordance with a study by Koyner et al. showing that the plasma NGAL concentration is inferior to urinary NGAL concentration in predicting AKI [50]. Taken as a whole these studies suggest a relevant role for urinary NGAL as a biomarker of AKI in cardiac surgery patients. However, a recent study by Friedrich et al. demonstrated that urinary NGAL failed to predict AKI in cardiac patients undergoing cardiopulmonary bypass and showed no correlation between urinary NGAL and postoperative AKI classification levels, even though urinary NGAL levels increased after surgery [49].

Although, both urinary and plasma NGAL levels are elevated in clinical conditions with AKI, studies indicate that urinary NGAL may be superior to plasma NGAL in diagnosing and predicting AKI. However, due to heterogeneity of studies and varying diagnostic criteria of AKI, a large variation of diagnostic accuracy has been reported with differing AUC’s (Table 2). Clerico et al. [15] reported AUC’s ranging from 0.54–0.96 for plasma NGAL and 0.61–0.98 for urine NGAL, indicating a large variation in the discrimination of patients with or without AKI. This may mainly be explained by enrolment of low numbers of patients, varying diagnostic criteria for the clinical endpoint AKI, different NGAL assays, non-standardised preanalytical variables (specimen type, storage and anticoagulants), and heterogenic study populations in relation to age and clinical setting.

NGAL in patients with heart failure

Growing evidence suggests that inflammation and matrix degradation in the myocardium play a pathogenic role in HF, which may be related to NGAL [6]. A summary of the studies on HF is provided in Table 4.

Table 4:

Neutrophil gelatinase associated-lipocalin studies on patients with heart failure.

Yndestad et al. [6] investigated the role of NGAL in 236 patients with acute post-MI HF and 150 patients with chronic HF. Patients in NYHA class III had significantly higher plasma NGAL levels than patients in NYHA class I or II and controls. Additionally, high baseline plasma NGAL levels were associated with an increased incidence of the composite endpoint (non-fatal MI, stroke, cardiovascular death, and all-cause death) at 27 months (median) follow-up. Finally, a significant association between plasma NGAL and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was reported. Similar results were found by Bolignano et al. [51] in elderly chronic HF patients.

In a recent study, the predictive value of baseline NGAL was assessed in 61 patients with chronic systolic HF [52]. The primary endpoint was a composite of cardiovascular death and admission for heart failure during 10.6 months (median) follow up. In 15 patients who reached the endpoint, higher baseline NGAL concentrations were observed. The study concluded that plasma NGAL may be a predictor of outcome in patients with HF. Furthermore, the study reported a positive correlation between plasma NGAL and creatinine, yet no association was observed between plasma NGAL and BNP. This finding is in agreement with Lindberg et al. who did not report any association between NGAL and NT-proBNP [56].

In chronic HF patients, urine NGAL levels at admission were associated with increased risk of subsequent worsening of renal function [53]. Another study reported that urinary NGAL was associated with a combined primary endpoint of all-cause mortality and HF hospitalisation in chronic HF patients [57]. Both studies indicated that urinary NGAL may be a direct marker of renal damage and tubulo-interstitial injury in chronic HF patients.

Nymo et al. [54] studied the prognostic value of serum NGAL in elderly with chronic ischaemic HF. When adjusted for demographic and clinical variables, NGAL concentration remained a significant predictor of adverse outcome. However, when adjusted for apolipoprotein A-1 (ApoA-1), estimated glomerular filtration rate (eGFR), hs-CRP, and NT-proBNP, this association was lost. The authors concluded that the clinical use of circulating NGAL in this study was limited.

Maisel et al. [55] investigated the prognostic value of plasma NGAL in patients with acute HF. Patients were followed for 30 days, and the primary combined endpoint was HF readmission or all-cause mortality. Baseline and discharge levels of NGAL were significantly elevated in patients with events compared to event-free patients. Patients with events also had higher BNP levels. The AUC by using ROC analysis was higher for NGAL [0.73] than for BNP [0.65], indicating that plasma NGAL is a good predictor of the combined endpoint after 30 days in acute HF patients. In addition, the combination of high-NGAL and high-BNP or high-NGAL and low-BNP was associated with higher risk of HF readmission or all-cause death than low-NGAL and low-BNP or low-NGAL and high-BNP.

Both plasma and urinary NGAL levels are increased in chronic HF patients. The elevation is dependent on the clinical stage of HF and the presence of renal failure. Plasma NGAL may amplify the predictive value of NT-proBNP and increase the risk of adverse outcome. Thus, the combined elevation of NGAL and NT-proBNP is associated with the worst outcome.

Overall, NGAL demonstrated a questionable discrimination between categories and disease severity of CVD. Discrepancies are also seen between urine and plasma NGAL, where the performance of urine NGAL in most studies is superior to plasma for determining AKI. These differences may be due to different origins of NGAL in urine and plasma in AKI and CVD. During AKI, NGAL is primarily secreted from the kidney, whereas the pool of NGAL in blood may originate from several sources including neutrophils during inflammation, which may contribute to the observed differences in performance of urine and plasma NGAL in AKI and CVD [58], [59].

Future perspectives

Based on the aforementioned studies, the potential clinical use of circulating NGAL in cardiac settings remains to be defined. Several factors may contribute to the diversity in NGAL levels and ultimately its association to endpoints. In the studies reviewed above, the heterogeneous subpopulations, lack of appropriate reference material for assay calibration, and potential differences in assay specificity towards the monomeric, dimeric, and heterodimeric forms of NGAL make direct comparisons challenging. While most studies measured NGAL levels at baseline, ideally, repetitive measurements of NGAL levels may enable monitoring of disease progression. Furthermore, this approach could provide additional information on the correlation with other inflammatory biomarkers and may also enhance the predictive value of NGAL. However, source and timing of blood sampling are still an issue in many studies investigating NGAL and CVD, since NGAL is most likely secreted at the site of active inflammation. Duration of CVD prior to study inclusion may also influence NGAL levels.

Further studies establishing standardised reference ranges for NGAL taking gender, age, and ethnicity into consideration are also warranted. Future research should also evaluate whether combinations of NGAL and cardiac biomarkers such as troponin and BNP provide stronger associations with clinical outcomes than conventional biomarkers. Future studies should specifically explore if incorporating NGAL into clinical care may benefit patient management.

Another aspect is to consider co-existing diseases such as malignancy, chronic kidney disease, and systemic inflammatory conditions, which may affect systemic NGAL levels and interfere with the association of NGAL and CVD. In this case, collection of data about whether patients were exposed to nephrotoxic agents is important.

Summary and conclusions

Despite preventive and therapeutic efforts, morbidity and mortality due to CVD remains an increasing challenge. Therefore, new biomarkers are warranted to identify CVD patients with an increased risk of cardiovascular events, which may guide therapeutic strategies to improve prognosis. NGAL has emerged as a promising biomarker of outcomes in CVD.

In previous studies, NGAL has performed as a more consistent predictor of adverse outcomes in patients with ACS, especially STEMI, compared with patients having stable CAD. This may indicate that NGAL is mainly secreted at active inflammatory sites, and is suggested as a complementary risk marker to NT-Pro-BNP and hs-CRP. These biomarkers along with NGAL may allow better prediction of outcomes in CAD patients.

NGAL may be a risk marker of AKI after cardiac surgery. The diagnostic/prognostic accuracy of NGAL in both AKI and CVD is varying in different studies illustrated by non-standardised reference ranges, measurement methods, different specimen types, anticoagulants, storage, and stability conditions, cohort size, clinical settings, and subpopulations. There is, however, ample evidence to support the use of urine NGAL in AKI [60]. While urine NGAL in AKI almost exclusively contain NGAL monomer from the kidney, the plasma/serum pool contain different NGAL complexes from several sources and would therefore be expected to show poorer diagnostic performance in AKI.

Although data suggest a potential role for NGAL as a biomarker in HF patients, further studies are needed to evaluate the prognostic relevance of this biomarker, as the majority of the aforementioned studies included only small patient groups.

Overall, the studies showed that urinary NGAL is primarily elevated in patients with AKI, while plasma/serum NGAL is significantly increased in patients with acute MI as well as stable CAD. Conversely, plasma NGAL still reflects AKI when the renal clearance of NGAL is decreased. In order to demonstrate associations between NGAL and outcomes independent of AKI, adjustments for kidney function, e.g. creatinine and/or eGFR or parallel measurements of NGAL in both urine and plasma are needed. However, a uniform AKI definition and timing of NGAL measurements in research studies are still needed.

Future studies may explore new therapeutic strategies using tailored treatment based on measurements of NGAL. Moreover, further studies should explore whether NGAL is a strong and specific marker of atherosclerosis.


  • 1.

    Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2016;352:1685–95. Google Scholar

  • 2.

    Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317–25. PubMedCrossrefGoogle Scholar

  • 3.

    Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387–97. CrossrefPubMedGoogle Scholar

  • 4.

    Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528–36. PubMedCrossrefGoogle Scholar

  • 5.

    Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136–42. CrossrefPubMedGoogle Scholar

  • 6.

    Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009;30:1229–36. CrossrefPubMedGoogle Scholar

  • 7.

    Haase-Fielitz A, Bellomo R, Devarajan P, Bennett M, Story D, Matalanis G, et al. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant 2009;24:3349–54. CrossrefPubMedGoogle Scholar

  • 8.

    Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994;83:799–807. PubMedGoogle Scholar

  • 9.

    Xu SY, Carlson M, Engstrom A, Garcia R, Peterson CG, Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest 1994;54:365–76. PubMedCrossrefGoogle Scholar

  • 10.

    Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10:1033–43. PubMedCrossrefGoogle Scholar

  • 11.

    Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006;19:211–5. CrossrefPubMedGoogle Scholar

  • 12.

    Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–503. PubMedCrossrefGoogle Scholar

  • 13.

    Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001;276:37258–65. CrossrefPubMedGoogle Scholar

  • 14.

    Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012–24. CrossrefPubMedGoogle Scholar

  • 15.

    Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012;50:1505–17. Google Scholar

  • 16.

    Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231–8. PubMedCrossrefGoogle Scholar

  • 17.

    Tuladhar SM, Puntmann VO, Soni M, Punjabi PP, Bogle RG. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol 2009;53:261–6. PubMedCrossrefGoogle Scholar

  • 18.

    Magnusson NE, Hornum M, Jorgensen KA, Hansen JM, Bistrup C, Feldt-Rasmussen B, et al. Plasma neutrophil gelatinase associated lipocalin (NGAL) is associated with kidney function in uraemic patients before and after kidney transplantation. BMC Nephrol 2012;13:8. PubMedCrossrefGoogle Scholar

  • 19.

    Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin Lab Invest 2010;70:374–82. CrossrefPubMedGoogle Scholar

  • 20.

    Hansen YB, Damgaard A, Poulsen JH. Evaluation of NGAL TestTM on Cobas 6000. Scand J Clin Lab Invest 2014;74:20–6. PubMedCrossrefGoogle Scholar

  • 21.

    Makris K, Stefani D, Makri E, Panagou I, Lagiou M, Sarli A, et al. Evaluation of a particle enhanced turbidimetric assay for the measurement of neutrophil gelatinase-associated lipocalin in plasma and urine on Architect-8000: Analytical performance and establishment of reference values. Clin Biochem 2015;48:1291–7. PubMedCrossrefGoogle Scholar

  • 22.

    Cullen MR, Murray PT, Fitzgibbon MC. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. Ann Clin Biochem 2012;49:190–3. PubMedCrossrefGoogle Scholar

  • 23.

    Zwiers AJ, de Wildt SN, de Rijke YB, Willemsen SP, Abdullahi NS, Tibboel D, et al. Reference intervals for renal injury biomarkers neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in young infants. Clin Chem Lab Med 2015;53:1279–89. PubMedGoogle Scholar

  • 24.

    Cangemi G, Storti S, Cantinotti M, Fortunato A, Emdin M, Bruschettini M, et al. Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform. Clin Chem Lab Med 2013;51:1101–5. PubMedGoogle Scholar

  • 25.

    Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15: 551–61. CrossrefPubMedGoogle Scholar

  • 26.

    Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers. Pediatr Nephrol 2015;30:677–85. CrossrefPubMedGoogle Scholar

  • 27.

    Pennemans V, Rigo JM, Faes C, Reynders C, Penders J, Swennen Q. Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population: are age and gender an issue? Clin Chem Lab Med 2013;51:1795–802. PubMedGoogle Scholar

  • 28.

    Rybi-Szuminska A, Wasilewska A, Litwin M, Kulaga Z, Szuminski M. Paediatric normative data for urine NGAL/creatinine ratio. Acta Paediatr 2013;102:e269–72. CrossrefPubMedGoogle Scholar

  • 29.

    Delanaye P, Rozet E, Krzesinski JM, Cavalier E. Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chim Acta 2011;412:390. CrossrefPubMedGoogle Scholar

  • 30.

    Huynh TK, Bateman DA, Parravicini E, Lorenz JM, Nemerofsky SL, Sise ME, et al. Reference values of urinary neutrophil gelatinase-associated lipocalin in very low birth weight infants. Pediatr Res 2009;66:528–32. PubMedCrossrefGoogle Scholar

  • 31.

    Stejskal D, Karpisek M, Humenanska V, Hanulova Z, Stejskal P, Kusnierova P, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res 2008;40:381–5. CrossrefPubMedGoogle Scholar

  • 32.

    Cavalier E, Bekaert AC, Carlisi A, Legrand D, Krzesinski JM, Delanaye P. Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory’s point of view. Clin Chem Lab Med 2011;49:339–41. PubMedGoogle Scholar

  • 33.

    Tarin C, Fernandez-Garcia CE, Burillo E, Pastor-Vargas C, Llamas-Granda P, Castejon B, et al. Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice. Cardiovasc Res 2016;111:262–73. CrossrefPubMedGoogle Scholar

  • 34.

    Folkesson M, Kazi M, Zhu C, Silveira A, Hemdahl AL, Hamsten A, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost 2007;98:427–33. PubMedGoogle Scholar

  • 35.

    Leclercq A, Houard X, Philippe M, Ollivier V, Sebbag U, Meilhac O, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007;82:1420–9. CrossrefPubMedGoogle Scholar

  • 36.

    Soylu K, Aksan G, Nar G, Ozdemir M, Gulel O, Inci S, et al. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Anatol J Cardiol 2015;15:450–5. PubMedCrossrefGoogle Scholar

  • 37.

    Sahinarslan A, Kocaman SA, Bas D, Akyel A, Ercin U, Zengin O, et al. Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coron Artery Dis 2011;22:333–8. CrossrefPubMedGoogle Scholar

  • 38.

    Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008;158:203–7. CrossrefPubMedGoogle Scholar

  • 39.

    Akcay AB, Ozlu MF, Sen N, Cay S, Ozturk OH, Yalcn F, et al. Prognostic significance of neutrophil gelatinase-associated lipocalin in ST-segment elevation myocardial infarction. J Investig Med 2012;60:508–13. CrossrefPubMedGoogle Scholar

  • 40.

    Lindberg S, Pedersen SH, Mogelvang R, Jensen JS, Flyvbjerg A, Galatius S, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2012;60:339–45. CrossrefPubMedGoogle Scholar

  • 41.

    Zykov MV, Kashtalap VV, Bykova IS, Hryachkova ON, Kalaeva VV, Shafranskaya KS, et al. Clinical and prognostic value of serum neutrophil gelatinase-associated lipocalin in patients with ST-segment elevation myocardial infarction. Kardiologiia 2016;56:24–9. PubMedGoogle Scholar

  • 42.

    Paulsson J, Dadfar E, Held C, Jacobson SH, Lundahl J. Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 2007;192:328–34. PubMedCrossrefGoogle Scholar

  • 43.

    Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009;104:917–20. PubMedCrossrefGoogle Scholar

  • 44.

    Woitas RP, Scharnagl H, Kleber ME, Delgado GE, Grammer TB, Pichler M, et al. Neutrophil gelatinase-associated lipocalin levels are U-shaped in the ludwigshafen Risk and Cardiovascular Health (LURIC) study-Impact for mortality. PLoS One 2017;12:e0171574. CrossrefPubMedGoogle Scholar

  • 45.

    Kafkas N, Demponeras C, Zoubouloglou F, Spanou L, Babalis D, Makris K. Serum levels of gelatinase associated lipocalin as indicator of the inflammatory status in coronary artery disease. Int J Inflam 2012;2012:189797. PubMedGoogle Scholar

  • 46.

    Katagiri M, Takahashi M, Doi K, Myojo M, Kiyosue A, Ando J, et al. Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. Heart Vessels 2015;31:1595–602. PubMedGoogle Scholar

  • 47.

    Xin C, Yulong X, Yu C, Changchun C, Feng Z, Xinwei M. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Ren Fail 2008;30:904–13. PubMedCrossrefGoogle Scholar

  • 48.

    Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007;11:R127. CrossrefPubMedGoogle Scholar

  • 49.

    Friedrich MG, Bougioukas I, Kolle J, Bireta C, Jebran FA, Placzek M, et al. NGAL expression during cardiopulmonary bypass does not predict severity of postoperative acute kidney injury. BMC Nephrol 2017;18:73. CrossrefPubMedGoogle Scholar

  • 50.

    Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008;74:1059–69. PubMedCrossrefGoogle Scholar

  • 51.

    Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009;12:7–14. PubMedCrossrefGoogle Scholar

  • 52.

    Villacorta H, Santos RA, Marroig MA, Pereira GP, Xavier AR, Kanaan S. Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure. Rev Port Cardiol 2015;34:473–8. PubMedGoogle Scholar

  • 53.

    Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008;10:997–1000. PubMedCrossrefGoogle Scholar

  • 54.

    Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. J Intern Med 2012;271:436–43. PubMedCrossrefGoogle Scholar

  • 55.

    Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011;13:846–51. CrossrefPubMedGoogle Scholar

  • 56.

    Lindberg S, Jensen JS, Mogelvang R, Pedersen SH, Galatius S, Flyvbjerg A, et al. Plasma neutrophil gelatinase-associated lipocalinin in the general population: association with inflammation and prognosis. Arterioscler Thromb Vasc Biol 2014;34:2135–42. CrossrefPubMedGoogle Scholar

  • 57.

    Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011;32:2705–12. CrossrefPubMedGoogle Scholar

  • 58.

    Cai L, Borowiec J, Xu S, Han W, Venge P. Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin Chim Acta 2009;403:121–5. CrossrefPubMedGoogle Scholar

  • 59.

    Cai L, Rubin J, Han W, Venge P, Xu S. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010;5:2229–35. CrossrefPubMedGoogle Scholar

  • 60.

    de Geus HR, Ronco C, Haase M, Jacob L, Lewington A, Vincent JL. The cardiac surgery-associated neutrophil gelatinase-associated lipocalin (CSA-NGAL) score: A potential tool to monitor acute tubular damage. J Thorac Cardiovasc Surg 2016;151:1476–81. CrossrefGoogle Scholar

About the article

Corresponding author: Nils Erik Magnusson, Associate Professor, MSc., PhD, The Medical Research Laboratories, Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Nørrebrogade 44, 8000 Aarhus C, Denmark

Received: 2017-02-10

Accepted: 2017-05-07

Published Online: 2017-06-23

Published in Print: 2017-11-27

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 56, Issue 1, Pages 5–18, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2017-0120.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Rui Zhang, Dan Han, Zhenyu Li, Chengwu Shen, Yahui Zhang, Jun Li, Genquan Yan, Shasha Li, Bo Hu, Jiangbing Li, and Ping Liu
Frontiers in Pharmacology, 2018, Volume 9
Takuma Miyamoto, Jamshid H. Karimov, and Kiyotaka Fukamachi
Expert Review of Medical Devices, 2018, Page 1
Branka Vulesevic, Martin G. Sirois, Bruce Allen, Simon de Denus, and Michel White
Canadian Journal of Cardiology, 2018
W. Eilenberg, S. Stojkovic, A. Piechota-Polanczyk, A. Kaider, N. Kozakowski, W. J. Weninger, J. Nanobachvili, J. Wojta, I. Huk, S. Demyanets, and C. Neumayer
Cardiovascular Diabetology, 2017, Volume 16, Number 1

Comments (0)

Please log in or register to comment.
Log in